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Abstract
Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and have demonstrated clinical util-
ity in the treatment of patients with osteolytic bone metastases. They also exhibit direct antitumor activity in vitro
and can reduce skeletal tumor burden and inhibit the formation of bone metastases in vivo. However, whether
such effects are caused by a direct action of bisphosphonates on tumor cells or indirectly through inhibition of
bone resorption remains unclear. To address this question, we used here a structural analog of the bisphospho-
nate risedronate, NE-58051, which has a bone mineral affinity similar to that of risedronate, but a 3000-fold lower
bone antiresorptive activity. In vitro, risedronate and NE-58051 inhibited proliferation of breast cancer and mela-
noma cell lines. In vivo, risedronate and NE-58051 did not inhibit the growth of subcutaneous B02 breast tumor
xenografts or the formation of B16F10 melanoma lung metastasis. In contrast to NE-58051, risedronate did inhibit
B02 breast cancer bone metastasis formation by reducing both bone destruction and skeletal tumor burden, in-
dicating that the antitumor effect of bisphosphonates is achieved mainly through inhibition of osteoclast-mediated
bone resorption.
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Introduction
Nitrogen-containing bisphosphonates (N-BPs), such as risedronate,
are a class of antiresorptive drugs routinely used in the treatment
of patients with lytic bone diseases, particularly metastatic disease
[1–3]. Chemically, N-BPs share a common P-C-P structure, in which
two phosphonate groups are linked to a central carbon atom [4].
This common backbone, together with one of the covalently bound
side chains (preferably a hydroxyl group), are essential for binding to
hydroxyapatite crystals in the skeleton [4]. Because of their high af-
finity for bone mineral, N-BPs quickly localize to the skeleton where
they act primarily through the inhibition of osteoclast-mediated bone
resorption, thus alleviating the tumor-associated bone destruction.
The potency of an N-BP to inhibit osteoclast-mediated bone resorp-
tion is determined by the nitrogen-containing side chain, which in-
teracts with farnesyl pyrophosphate synthase (FPPS), a key enzyme in
the mevalonate pathway, thereby blocking the activity of this enzyme.
This leads to the inhibition of the prenylation of small GTPases im-
portant for osteoclast cell functions and survival [5,6]. In addition,
there is now extensive preclinical evidence that these agents exert di-
rect antitumor effects in vitro, inhibiting tumor cell adhesion, inva-
sion, and proliferation and inducing apoptosis [1,7]. They are also
able to reduce skeletal tumor burden and inhibit the formation of
bone metastases in a variety of animal models [8]. Furthermore, bis-
phosphonates may also act indirectly on tumor cells through antiangio-
genic [9–11] and/or immunomodulatory mechanisms [12,13].
The exact mechanism(s) responsible for the observed antitumor
effects of N-BPs in preclinical models remains unclear. Inhibition
of osteoclast-mediated bone resorption by bisphosphonates leads to
a reduced release of bone-derived growth factors, ultimately altering
the bone microenvironment [14,15] and thus affecting the ability of
tumor cells to grow in bone. It is therefore likely that the antitumor
activity of N-BPs in bone is mainly caused by inhibition of osteoclast
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activity [16,17]. However, some studies have demonstrated non–
skeletal-related antitumor activity ofN-BPs [18–21], suggesting that bis-
phosphonates can act directly on tumor cells in vivo, probably through
inhibition of the prenylation of small GTPases in tumor cells [8].
We have previously suggested that the high affinity of bisphospho-
nates for bone mineral limits their direct antitumor potential in vivo
[22]. This assumption is sustained by the observation that the treat-
ment of animals bearing bone metastases with a phosphonocarbox-
ylate analog of the N-BP risedronate, NE-10790, which has a low
bone mineral affinity, substantially reduces skeletal tumor growth
at a dosage that does not inhibit osteolysis [22]. In this previous
study [22], we reasoned that a bisphosphonate possessing weak bone
mineral affinity could be released in higher concentration near the
bone mineral surface and might act directly on tumor cells that reside
in the bone marrow. To further address this question, we propose
here to use the opposite strategy and treat animals bearing bone me-
tastases with a bisphosphonate that binds to bone but does not in-
hibit osteoclast-mediated bone resorption.
We used here risedronate and its structural analog, NE-58051, a
bisphosphonate in which the nitrogen-containing side chain is in-
creased by one methylene group inducing a more than 3000-fold de-
crease of its antiresorptive potency while maintaining a high affinity
for the bone mineral [23]. At the molecular level, contrary to risedro-
nate, NE-58051 is a poor inhibitor of FPPS [24]. Here, we compared
the effects of risedronate and NE-58051 on cancer cell proliferation
in vitro and on osteolysis and skeletal tumor growth in vivo, using a
mouse model of human breast cancer bone metastasis. The effects of a
therapy with risedronate or NE-58051 were also compared in animal




acid] and the analog NE-58051 [3-(3-pyridil)-1-hydroxypropylidene-
bisphosphonic acid]were kindly providedbyProcter&GamblePharma-
ceuticals (Cincinnati, OH). Stock solutions of bisphosphonates were
prepared in phosphate-buffered saline (PBS; pH 7.4; Invitrogen, Paisley,
UK), stored at 4°C, and filter-sterilized before use. Farnesol (FOH) and
geranylgeraniol (GGOH) were purchased from Sigma (St Louis, MO).
Cells
Breast cancer and melanoma cell lines (MDA-MB-231, ZR-75-1,
Hs578T, MCF-7, 4T1, MDA-MB-435s, and B16-F10) were pur-
chased from the American Type Culture Collection (Rockville, MD).
The B02-GFP/βGal cell line, a subpopulation of the human MDA-
MB-231 breast cancer cell line stably transfected to express luciferase
and green fluorescent protein (GFP), which possesses a high propensity
to induce osteolytic lesions in nude mice after intravenous tumor in-
oculation, has been described elsewhere [25,26]. Cells were cultured
under standard conditions and maintained in a humidified incubator
in an atmosphere of 5% CO2 at 37°C.
Cell Proliferation Assays
Cell proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay as previously described
[9]. Briefly, cells (500 cells/well) were seeded in 96-well plates and left
to adhere for 24 hours. Growing cells were then washed and incubated
for 6 days in the absence or in the presence of increasing concentra-
tions (0.001-10 mM) of risedronate or NE-58051. After treatment,
cell viability was assessed by the MTT incorporation method. MTT
(0.5 mg/ml) is transformed by mitochondrial dehydrogenases in living
cells to a blue formazan product spectrophotometrically measurable at
570 nm. Optical density was measured using a 96-well plate reader
(MR7000; Dynatech, Chantilly, VA). Half-maximal inhibitory concen-
tration (IC50) of each drug was calculated by logarithmic regression
from the dose-response curves. All of the experiments were run in sex-
tuplicate. Results are expressed as mean values ± SD of three indepen-
dent experiments.
To analyze the effects of the mevalonate pathway intermediates
FOH and GGOH on the antiproliferative activity of bisphosphonates,
B02-GFP/βGal cells were exposed to risedronate or NE-58051, using
their IC50 concentrations, in the presence or in the absence of FOH
(10 μM) and GGOH (10 μM), respectively. After 6 days of treatment,
growth inhibition was analyzed by using a MTT assay, as described
above. Data are presented as percentage of control.
Animal Models and Drug Treatments
Four-week-old female BALB/c athymic (nu/nu) and C57BL/6
mice were purchased from Charles River (St Germain sur l’Arbresle,
France). All procedures involving mice including their housing and
care, the method by which they were killed, and experimental proto-
cols were conducted in accordance with a code of practice established
by the local ethical committee (Comité Régional d’Ethique pour
l’Expérimentation Animale). These studies were routinely inspected
by the attending veterinarian to ensure continued compliance with
the proposed protocols.
Animal model of bone metastasis. The bone metastasis experi-
ments in mice were conducted as previously described [22,25,26].
Briefly, mice (athymic BALB/c) were randomly assigned to treatment
groups, and B02-GFP/βGal cells (5 × 105 cells in 100 μl of PBS)
were injected into the tail vein of anesthetized mice on day 0 of
the protocol. Risedronate or NE-58051 was given at a daily dose of
150 μg/kg body weight to animals beginning on day 0 and continued
until the end of the protocol (day 35). Drugs were administered by
subcutaneous injection in 100 μl of PBS (vehicle). Control mice re-
ceived a daily treatment with vehicle only. On day 35 after tumor cell
inoculation, radiographs of anesthetized mice were taken with the use
of MIN-R2000 film (Kodak, Rochester, NY) in an MX-20 cabinet
x-ray system (Faxitron X-ray Corp, Wheeling, IL), and osteolytic le-
sions were identified on radiographs as demarcated radiolucent lesions
in the bone. The area of osteolytic lesions on the skeleton of each
animal was measured using a Visiolab 2000 computerized image anal-
ysis system (Explora Nova, La Rochelle, France), and the extent of
bone destruction per animal was expressed in square millimeters, as
described previously [22,25,26]. Anesthetized mice were killed by cer-
vical dislocation after radiography on day 35, and hind limbs of ani-
mals were collected for further histologic analysis.
Animal model of tumorigenesis. B02-GFP/βGal cells (5 × 106
cells in 100 μl of PBS) were inoculated subcutaneously into the right
flank of anesthetized BALB/c mice. On day 35 of the protocol, at the
time tumor xenografts became palpable, animals were treated subcu-
taneously with a daily dose of 150 μg/kg risedronate or NE-58051
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until the end of the protocol (day 60). Control animals were treated
with the vehicle only. Tumor size was measured periodically, and
anesthetized mice were killed by cervical dislocation on day 60.
Animal model of lung metastasis. B16-F10 melanoma cells (106
cells in 100 μl of PBS) were injected intravenously to anesthetized
C57BL/6 mice. NE-58051 (at a dosage of 350 μg/kg per day) was
administered to animals by subcutaneous injection beginning on the
day of tumor cell inoculation (day 0) and continued until the end of
the protocol (day 14). Control animals were treated with the vehicle
only. Anesthetized mice were killed by cervical dislocation on day 14,
and lungs of animals were collected for further histologic analysis.
In Vivo Noninvasive Imaging and Image Analysis
In vivo optical imaging of mice engrafted with B02-GFP/βGal
cells was performed as described previously [26]. Briefly, animals
bearing B02-GFP/βGal metastases were examined at day 35 after cell
inoculation by noninvasive, whole-body fluorescence imaging using a
fluorescence scanning system (FluorImager; Amersham Biosciences,
Sunnyvale, CA). Scanned images were then analyzed using the comput-
erized image analysis system ImageQuant (Amersham Biosciences).
Microcomputed Tomography Imaging
Hind limbs from animals bearing radiographically confirmed tu-
mors were dissected and fixed in 80% (vol./vol.) alcohol. The bone
mineral density of tibiae with radiographic evidence of osteolytic le-
sions was analyzed by peripheral quantitative computed tomography
(CT) with the use of an XCT Research SA+ scanner (Stratec Medizin-
technik, Pforzheim, Germany) fitted with a 0.5-mm collimator, as pre-
viously described [27].
Bone Histology and Histomorphometry
Bone histologic diagnosis and histomorphometric analysis of bone
tissue sections were performed as previously described [25,26]. Briefly,
hind limbs from animals fixed in 80% (vol./vol.) alcohol were dehy-
drated and embedded in methylmethacrylate. A microtome (Polycut E;
Reichert-Jung, Heidelberg, Germany) was used to cut 7-μm-thick sec-
tions of undecalcified long bones, and the sections were stained with
Goldner trichrome [25,26].
Histologic and histomorphometric analyses were performed on
Goldner trichrome–stained longitudinal medial sections of tibial meta-
physis with the use of a computerized image analysis system (Visiolab
2000), as previously described [25,26]. Histomorphometric measure-
ments (i.e., bone volume–to–tissue volume [BV/TV] and tumor burden–
to–soft tissue volume [TB/STV] ratios) were performed in a standard
zone of the tibial metaphysis, including cortical and trabecular bones.
The BV/TV ratio represents the percentage of bone tissue out of total
tissue. The TB/STV ratio represents the percentage of tumor tissue out
of total soft tissue.
Measurement of a Biochemical Marker of Bone Turnover
Serum C-terminal cross-linked telopeptide of type I collagen (s-
CTX-I), a biochemical marker of collagen degradation, was measured
in the bone marrow from mice treated with a bisphosphonate (risedro-
nate or NE-58051) or the vehicle only. Bone marrow from metastatic
and nonmetastatic legs was flushed with PBS (100 μl), and CTX-I
levels were measured by a competitive ELISA using an antibody raised
against an eight–amino acid sequence of type I collagen C-telopeptide
(Nordic Bioscience a/s, Herlev, Denmark) according to the manufac-
turer’s protocol.
Statistical Analysis
All data were analyzed with the use of StatView software (version 5.0;
SAS Institute, Inc, Cary, NC). Pairwise comparisons were carried out
by performing a nonparametric Mann-Whitney U test. P < .05 were
considered statistically significant. All statistical tests were two-sided.
Results
Effects of Risedronate and NE-58051 on Tumor
Cell Proliferation
We compared the effects of risedronate and its structural analog
NE-58051 (Figure 1A), which is 60-fold less potent than risedronate
at inhibiting FPPS activity [24], on proliferation of various cancer cell
lines. Cells were treated with increasing concentrations of risedronate
or NE-58051, and cell viability was measured by MTT assay. Both
drugs induced a dose-dependent inhibition of cell growth in all tested
cell lines (Figure 1B). Irrespective of the cell line used, risedronate was
more potent in inhibiting cell proliferation than NE-58051, as dem-
onstrated by their respective IC50 (half-maximal inhibitory concentra-
tion) values (Table 1). Moreover, cell response to risedronate treatment
differed between cell lines, with some cell lines reacting more sensitively
to the treatment than others. Conversely, this effect was much less pro-
nounced in NE-58051–treated cells (Table 1 and Figure 1B).
We next investigated whether the inhibition of proliferation ob-
served with risedronate and NE-58051 could be reversed by cotreating
cells with metabolites of the mevalonate pathway downstream of
FPPS: FOH and GGOH. FOH and GGOH are converted to farnesyl
diphosphate (FPP) and geranylgeranyl diphosphate (GGPP) in cells;
however, unlike FPP and GGPP, the free isoprenols FOH and GGOH
are able to enter the cells easily [28] and can thus be used for prenyla-
tion of small GTP binding proteins through a salvage pathway. B02-
GFP/βGal cells were treated simultaneously with a bisphosphonate at
its IC50 concentration and 10 μM of FOH or GGOH, respectively.
FOH did not reverse the inhibition of proliferation induced by risedro-
nate (Figure 1C). However, GGOH partially rescued the proliferation
of B02-GFP/βGal cells when added to the culture medium simulta-
neously with risedronate (58% viability of risedronate/GGOH-treated
cells vs 28% viability of cells treated with risedronate only; P < .01). In
contrast, FOH andGGOHhad no effect on cell viability of NE-58051–
treated cells (Figure 1C).
Effects of Risedronate and NE-58051 on the Formation of
Breast Cancer Bone Metastases
We used a mouse model of human breast cancer bone metastasis in
which animals display radiographic evidence of osteolytic lesions in
hind limbs 18 days after tumor cell injection [25,26]. We compared
the effects of a daily dosing regimen of risedronate or NE-58051 on
the formation of breast cancer bone metastases, using a preventive pro-
tocol in which drug administration was initiated on the day of tu-
mor cell inoculation (Figure 2A). Radiographic analysis of hind legs
at the end of the treatment period (day 35) revealed that mice treated
daily with 150 μg of risedronate/kg body weight developed signifi-
cantly smaller osteolytic lesions compared with mice treated with the
same dosing regimen of NE-58051 or with the vehicle (mean area of
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osteolytic lesion: risedronate, 0.0 ± 0.0 mm2; NE-58051, 5.0 ±
0.9 mm2; vehicle, 4.8 ± 0.6 mm2; P < .0005 for risedronate vs vehicle;
Table 2 and Figure 2B). Reconstruction of hind legs using micro-CT
analysis confirmed x-ray results; hind legs from mice treated with rise-
dronate showed a marked increase in bone volume compared with
those of mice treated with vehicle or with the daily regimen of NE-
58051 (Figure 2C). Histomorphometric analysis of metastasis-bearing
hind limbs revealed that mice treated with risedronate also had a sta-
tistically significantly higher bone volume, as judged by BV/TV ratios,
when compared with that observed in mice treated with vehicle (eight-
fold increase; risedronate, 69.2% ± 3.8% vs vehicle, 9.1% ± 1.5%, P <
.005), whereasmice treatedwithNE-58051 did not (BV/TVNE-58051,
Table 1. IC50 of Risedronate and NE-58051 for Growth Inhibition of Human Breast and Mel-
anoma Cell Lines In Vitro.
Cell Line IC50 (mM)*
Risedronate [22] NE-58051
B02-GFP/βGal 0.37 ± 0.04 0.61 ± 0.03
MDA-MB-231 0.24 ± 0.09 0.64 ± 0.04
ZR-75-1 0.25 ± 0.06 0.58 ± 0.13
Hs578T 0.17 ± 0.04 0.49 ± 0.03
MCF-7 0.07 ± 0.01 0.39 ± 0.05
MDA-MB-435s 0.01 ± 0.00 0.46 ± 0.08
B16-F10 0.08 ± 0.02 0.17 ± 0.01
*Results are expressed as the mean ± SD from three independent experiments.
Figure 1. Effects of risedronate and NE-58051 on proliferation of breast and melanoma cells in vitro. (A) Chemical structures of rise-
dronate and NE-58051. (B) Dose-dependent inhibition of cancer cell proliferation after a 6-day treatment with 0.001 to 10 mM risedro-
nate or NE-58051, as measured by MTT proliferation assay. Results are the mean of three independent experiments. (C) Effects of the
mevalonate pathway intermediates FOH and GGOH on the inhibition of B02-GFP/βGal cell proliferation induced by risedronate or NE-
58051. B02-GFP/βGal cells were treated with a bisphosphonate at its IC50 concentration with or without adding 10 μM FOH or GGOH,
respectively. Results are expressed as the mean OD570nm ± SD of one experiment. *P< .001 when compared with the cells treated only
with the corresponding drug, using an unpaired Student’s t test.
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15.0% ± 2.7%; Table 2 and Figure 2D). In addition, assessment of
bone resorption markers in the bone marrow of mice treated with rise-
dronate showed that a daily treatment with the bisphosphonate sig-
nificantly reduced CTX-I levels, indicating that risedronate inhibited
bone resorption in animals. In contrast, CTX-I levels in NE-58051–
treated mice were similar to those of placebo-treated animals (Figure 3).
With regard to skeletal tumor burden, external fluorescence imag-
ing of mice bearing B02 bone metastases revealed that a daily regimen
Figure 2. Effects of risedronate and NE-58051 on bone metastasis formation. (A) Treatment protocol for bisphosphonates in a mouse
model of human B02 breast cancer cell metastasis to bone. B02-GFP/βGal cells were inoculated intravenously into 4-week-old female
BALB/c nude mice on day 0 (D0). Bisphosphonates were administered daily by subcutaneous injection beginning on D0. Mice were
killed 35 days after tumor cell inoculation (D35). (B) Representative radiographic images of hind limbs on day 35 after cell inoculation
from mice bearing B02-GFP/βGal bone metastases treated with risedronate or NE-58051. Arrows indicate osteolytic lesions. (C) Micro-
CT reconstruction of hind limbs obtained from different mice on day 35. Representative images for each group are shown. (D) Micro-
graphs of Goldner trichrome–stained sections of tibial metaphysis. For histologic tissue sections, bone is stained green, whereas bone
marrow and tumor cells (asterisk) are stained red. (E) Fluorescence analyses of B02-GFP/βGal tumor cells residing in bone. Arrows
indicate fluorescent tumor cells. The images shown are examples that best illustrate the effects of the treatments.
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of risedronate significantly reduced the number of B02-GFP/βGal cells
detected in the hind limbs of animals compared with vehicle-treated
mice (area of tumor burden: 6.3 ± 2.4 mm2 for risedronate vs 20.9 ±
3.0 mm2 for vehicle; Table 2 and Figure 2E). In contrast, NE-58051
at the same dosing regimen had no statistically significant inhibitory
effect on tumor burden (tumor area, 20.4 ± 3.2 mm2; Table 2 and
Figure 2E ). Histomorphometric analyses of metastatic hind limbs
confirmed fluorescence analyses, showing that a daily regimen of rise-
dronate reduced by 75% the tumor burden, as judged by the measure-
ment of TB/STV ratio, compared with vehicle (P < .0005), whereas
the TB/STV ratio of mice treated with NE-58051 was similar to that
of vehicle-treated animals (Table 2). Furthermore, histologic examina-
tion of Goldner trichrome–stained bones from placebo or NE-58051–
treated animals showed that an important part of the cancellous bone,
as well as some cortical bone in proximal tibiae, was destroyed and
replaced by tumor cells that filled the bone marrow cavity (Figure 2D).
In contrast, cortical bone remained intact and there was a substantial
increase in trabecular bone in legs from risedronate-treated animals. In
addition, only few small tumor foci were localized in the bone marrow
cavity (Figure 2D).
Aside from our observation that risedronate decreased skeletal B02-
GFP/βGal tumor burden at a dose of 150 μg of risedronate/kg body
(Table 2 and Figure 2, D and E), the effects of a therapy with rise-
dronate or NE-58051 were also compared in animal models of breast
cancer tumorigenesis and melanoma lung metastasis. The same total
cumulative dose of risedronate or NE-58051 was given to each mouse,
regardless of the dosing regimens, which enabled us to directly com-
pare the efficacy of risedronate and NE-58051 among the different
animal models of bone and lung metastases, and tumorigenesis. We
found that neither risedronate nor NE-58051 was able to inhibit the
growth of subcutaneous B02-GFP/βGal tumor xenografts in animals
(Figure 4A). Moreover, similar to previous results obtained with rise-
dronate [22], NE-58051 given daily at a dose of 350 μg/kg body
weight did not inhibit the formation of B16-F10 lung metastases in
animals (Figure 4B).
Discussion
N-BPs are highly effective therapeutic agents routinely used for the
treatment of bone disorders, particularly tumor-induced bone disease.
In addition, N-BPs also have antitumor activity, reducing skeletal tu-
mor burden and inhibiting the formation of bone metastases in vivo.
However, whether N-BPs achieve this effect by acting directly on tu-
mor cells in vivo or indirectly through inhibition of bone resorption
remains unclear. Using a phosphonocarboxylate analog of the N-BP
risedronate, NE-10790, we have previously shown that a bisphospho-
nate possessing weak bone mineral affinity is released in higher con-
centration near the bone mineral surface and acts directly on tumor
cells that reside in the bone marrow, reducing skeletal tumor growth
at a dosage that does not inhibit osteolysis [22]. In the present study,
we used the opposite strategy and compared the antitumor effect of
risedronate with that of NE-58051, a structural analog of risedronate
with a bone mineral affinity similar to that of risedronate, but having a
3000-fold lower antiresorptive capacity [23,24].
We found that both risedronate and NE-58051 induced a dose-
dependent inhibition of cancer cell proliferation in vitro. The higher
potency of risedronate in inhibiting cancer proliferation, compared
with NE-58051, correlated with the higher capacity of this com-
pound to inhibit FPPS activity. These results were in favor of the
established view that N-BPs, such as risedronate and zoledronate,
act on cancer cells through inhibition of FPPS. NE-58051, however,
which lacks the ability to inhibit FPPS, achieved its antiproliferative
effect on cancer cell lines through a mechanism independent of the
mevalonate pathway. This hypothesis was further supported by our
observation that NE-58051–induced growth inhibition of B02-GFP/
βGal cells could not be reversed by replenishing cells with metabolites
of the mevalonate pathway downstream of FPPS. Conversely, cotreat-
ment withGGOH,which restores geranylgeranylation, partially rescued
the inhibition of cell proliferation caused by risedronate. However, if
risedronate acted solely through inhibition of FPPS, we would have
expected GGOH to have rescued risedronate-treated cancer cells more
Table 2. Effects of Risedronate and NE-58051 on the Extent of Osteolytic Lesions and Skeletal Tumor Burden in Animals Bearing B02-GFP/βGal Breast Cancer Cells*.
Treatment Radiography (mm2/mouse) Fluorescence (mm2/mouse) Histomorphometry
BV/TV (%) TB/STV (%)
Vehicle 4.8 ± 0.6 (n = 11) 20.9 ± 3.0 (n = 11) 9.1 ± 1.5 (n = 9) 20.5 ± 5.6 (n = 9)
Risedronate 0.0 ± 0.0† (n = 7) 6.3 ± 2.4‡ (n = 7) 69.2 ± 3.8† (n = 7) 5.3 ± 3.5† (n = 7)
NE-58051 5.0 ± 0.9 (n = 5) 20.4 ± 3.2 (n = 5) 15.0 ± 2.7 (n = 5) 16.5 ± 9.8 (n = 5)
*Data are expressed as mean values ± SEM from two independent experiments. All measurements were made 35 days after tumor cell injection. P values (two-sided) are for pairwise comparisons with
vehicle-treated control group using the Mann-Whitney U test. BV/TV indicates bone volume–to–tissue volume ratio; TB/STV, tumor burden (bone metastasis volume)–to–soft tissue volume ratio.
†P < .0005, compared with vehicle-treated group.
‡P < .005, compared with vehicle-treated group.
Figure 3. Measurement of CTX-I levels in the bone marrow from
mice treated with risedronate, NE-58051, or vehicle only. Bone mar-
row frommetastatic and nonmetastatic legs was flushed, and CTX-I
levels were measured by a competitive ELISA using an antibody
raised against an eight–amino acid sequence of type I collagen
C-telopeptide. Bars indicate the average value. *P < .05.
576 Bone Metastasis Inhibition by Bisphosphonates Fournier et al. Neoplasia Vol. 12, No. 7, 2010
than what we observed. Similar findings have been previously reported
with the inhibitory action of the N-BPs pamidronate and olpadronate
on osteoclast activity, which are only minimally reversible with GGOH
[29]. Altogether, these results ([29] and data presented here) suggest
that although bisphosphonates act largely through inhibition of FPPS
in cancer cells (and osteoclasts), an additional mechanism independent
of the prenylation of small GTPases may occur. This contention is in
line with a recent study by Bivi et al. [30] showing that N-BPs (rise-
dronate, alendronate, and ibandronate) target proteins such as tubulin
cofactor B and ASK/DBF4 (activator of S-phase kinase). Previous stud-
ies have also suggested protein tyrosine phosphatases to be inhibited by
alendronate [31,32].
We have previously shown that soluble bisphosphonates are sig-
nificantly more potent than mineral-bound bisphosphonates at in-
hibiting tumor cell adhesion to bone in vitro [33], and as mentioned
before, we also showed that the direct antitumor activity of bisphos-
phonates is increased in vivo by lowering their bone mineral affinity
[22]. NE-58051 has a bone mineral affinity similar to that of risedro-
nate [23], and it does not inhibit bone resorption in vivo [24]. We
showed here that NE-58051 inhibited tumor cell proliferation in vitro
(Figure 1). However, the treatment of tumor-bearing mice with NE-
58051 did not inhibit bone destruction or reduce skeletal tumor bur-
den, as opposed to a bisphosphonate therapy with risedronate. The
in vivo antitumor activity of risedronate was restricted to bone be-
cause it did not inhibit the growth of subcutaneous B02-GFP tumor
xenografts (Figure 4A) or the formation of B16-F10 melanoma lung
metastases [22]. Using CTX as a surrogate marker of bone resorp-
tion (Figure 3), risedronate inhibited bone destruction, which sub-
sequently deprived B02 breast cancer cells of bone-derived growth
factors required for tumor cell proliferation. Our results are therefore
in favor of an indirect antitumor effect of risedronate, once it is bound
to bone mineral. However, bisphosphonates do possess antitumor
properties [1,8]. For example, zoledronate decreases tumor growth
in bone in osteoclast-defective mice [34]. In addition, we have previ-
ously shown that bisphosphonate therapy with zoledronate at a high
dosage with a long dosing interval reduces osteolysis by inhibiting
bone resorption, whereas therapy at a low dosage with a more fre-
quent dosing interval can also directly affect the growth of tumor cells
resident in bone [27]. We believe that a frequent low-dose therapy
with N-BPs facilitates the prolonged exposure of cancer cells to the
drug. Such an assumption is in agreement with the fact that decreas-
ing the bone mineral affinity of bisphosphonates is an effective ther-
apeutic strategy to minimize skeletal tumor growth in vivo [22]. Here,
given the high daily dose of risedronate administered to animals, we
surmise that this N-BP also has the potential to exhibit a direct anti-
tumor effect in vivo. However, this direct antitumor effect of rise-
dronate should only occur through inhibition of FPPS activity because
NE-58051, under similar experimental conditions, did not exhibit
any antitumor activity in vivo. The inhibitory mechanisms of N-BPs
that are independent of the prenylation of small GTPases therefore
seem to play only a minimal role in vivo.
In conclusion, our study provides evidence that the antitumor ef-
fect of bisphosphonates can be achieved mainly through inhibition of
osteoclast-mediated bone resorption. However, once released into the
bone marrow cavity, bisphosphonates can also directly target cancer
cells through inhibition of the mevalonate pathway. In this regard,
the use of compounds with a low bone mineral affinity, which are
able to target FPPS, may open new ways to maximize the antitumor
activity of bisphosphonates in cancer therapy.
Figure 4. (A) Effect of risedronate and NE-58051 on growth of sub-
cutaneous breast cancer xenografts in nude mice. B02-GFP/βGal
cells were inoculated subcutaneously into the right flank of ani-
mals. Animals received daily doses of 150 μg/kg risedronate or
NE-58051 from day 35, when tumors became palpable, until the
end of the protocol (D60). Control animals were treated with the
vehicle only. None of the drugs inhibited the growth of B02 breast
cancer cells in vivo. Results are the mean ± SD of five animals per
group. (B) Effect of NE-58051 on lung metastasis formation. B16-
F10 melanoma cells were injected intravenously to C57BL/6 mice.
NE-58051 (at a dosage of 350 μg/kg per day) was administered to
animals by subcutaneous injection beginning on the day of tumor
cell inoculation (D0), and continuing until the end of the protocol
(D14). Control animals (placebo) were treated with the vehicle
only. Visible pigmented melanoma lung metastases were enu-
merated. Inset: images shown are examples that best illustrate
metastatic lungs in each group. NE-58051 did not inhibit B16-
F10 lung metastasis. Results are the mean ± SD of five animals
per group.
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